[1]
|
D. F. Ransohoff and W. A. Gracie, “Treatment of Gallstones,” Annals of Internal Medicine, Vol. 119, No. 7, 1993, pp. 606-619.
|
[2]
|
C. D. Anderson, M. H. Rice, C. W. Pinson, et al., “Fluorodeoxyglucose PET Imaging in the Evaluation of Gallbladder Carcinoma and Cholangiocarcinoma,” Journal of Gastrointestinal Surgery, Vol. 8, No. 1, 2004, pp. 90-97. doi:10.1016/j.gassur.2003.10.003
|
[3]
|
K. M. Reid, M.A. de la Ramos and J. H. Donohue, “Diagnosis and Surgical Management of Gallbladder Cancer: A Review,” Journal of Gastrointestinal Surgery, Vol. 11, No. 5, 2007, pp. 671-681.
doi:10.1007/s11605-006-0075-x
|
[4]
|
G. Randi, S. Franceschi and V. C. La, “Gallbladder Cancer Worldwide: Geographical Distribution and Risk Factors,” International Journal of Cancer, Vol. 118, No. 7, 2006, pp. 1591-1602. doi:10.1002/ijc.21683
|
[5]
|
X. de Aretxabala, I Roa, L. Burgos, et al., “Gallbladder Cancer: An Analysis of a Series of 139 Patients with Invasion Restricted to the Subserosal Layer,” Journal of Gastrointestinal Surgery, Vol. 10, No. 2, 2006, pp. 186-192. doi:10.1016/j.gassur.2005.11.003
|
[6]
|
K. L. Mekeel and A. W. Hemming, “Surgical Management of Gallbladder Carcinoma: A Review,” Journal of Gastrointestinal Surgery, Vol. 11, No. 9, 2007, pp. 1188-1193. doi:10.1007/s11605-007-0115-1
|
[7]
|
H. Onoyama, M. Yamamoto, M. Takada, et al., “Diagnostic Imaging of Early Gallbladder Cancer: Retrospective Study of 53 Cases,” World Journal of Surgery, Vol. 23, No. 7, 1999, pp. 708-712. doi:10.1007/PL00012373
|
[8]
|
S. Kondo, Y. Nimura, N. Hayakawa, et al., “Regional and Para-Aortic Lymphadenectomy in Radical Surgery for Advanced Gallbladder Carcinoma,” British Journal of Surgery, Vol. 87, No. 4, 2000, pp. 418-422.
doi:10.1046/j.1365-2168.2000.01384.x
|
[9]
|
M. C. Misra and S. Guleri, “Management of Cancer Gallbladder Found as a Surprise on a Resected Gallbladder Specimen,” Journal of Surgical Oncology, Vol. 93, No. 8, 2006, pp. 690-698. doi:10.1002/jso.20537
|
[10]
|
E. C. Lazcano-Ponce, J. F. Miquel, N. Munoz, et al., “Epidemiology and Molecular Pathology of Gallbladder Cancer,” CA: A Cancer Journal for Clinicians, Vol. 51, No. 6, 2001, pp. 349-364.
doi:10.3322/canjclin.51.6.349
|
[11]
|
F. Levi, F. Lucchini, E. Negri and V. C. La, “The Recent Decline in Gallbladder Cancer Mortality in Europe,” European Journal of Cancer Prevention, Vol. 12, No. 4, 2003, pp. 265-267.
doi:10.1097/00008469-200308000-00004
|
[12]
|
W. H. Chow, C. Johansen, G. Gridley, et al., “Gallstones, Cholecystectomy and Risk of Cancers of the Liver, Biliary Tract and Pancreas,” British Journal of Cancer, Vol. 79, 1999, pp. 640-644. doi:10.1038/sj.bjc.6690101
|
[13]
|
D. L. Bartlett, Y. Fong, J. G. Fortner, et al., “Long-Term Results after Resection for Gallbladder Cancer. Implications for Staging and Management,” Annals of Surgery, Vol. 224, No. 5, 1996, pp. 639-646.
doi:10.1097/00000658-199611000-00008
|
[14]
|
A. K. Diehl, “Gallstone Size and the Risk of Gallbladder Cancer,” Journal of the American Medical Association, Vol. 250, No. 17, 1983, pp. 2323-2326.
doi:10.1001/jama.1983.03340170049027
|
[15]
|
C. J. Moerman, M. P. Berns, H. B. Bueno de Mesquita and S. Runia, “Reproductive History and Cancer of the Biliary Tract in Women,” International Journal of Cancer, Vol. 57, No. 2, 1994, pp. 146-153.
doi:10.1002/ijc.2910570203
|
[16]
|
M. Pandey and V. K. Shukla, “Lifestyle, Parity, Menstrual and Reproductive Factors and Risk of Gallbladder Cancer,” European Journal of Cancer Prevention, Vol. 12, No. 4, 2003, pp. 269-272.
doi:10.1097/00008469-200308000-00005
|
[17]
|
E. E. Calle, C. Rodriguez, K. Walker-Thurmond and M. J. Thun, “Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults,” The New England Journal of Medicine, Vol. 348, 2003, pp. 1625-1638. doi:10.1056/NEJMoa021423
|
[18]
|
K. Yagyu, Y. Lin, Y Obata, et al., “Bowel Movement Frequency, Medical History and the Risk of Gallbladder Cancer Death: A Cohort Study in Japan,” Cancer Science, Vol. 95, No. 8, 2004, pp. 674-678.
doi:10.1111/j.1349-7006.2004.tb03328.x
|
[19]
|
A. Muratore, R. Polastri and L. Capussotti, “Radical Surgery for Gallbladder Cancer: Current Options,” European Journal of Surgical Oncology, Vol. 26, No. 5, 2000, pp. 438-443. doi:10.1053/ejso.1999.0918
|
[20]
|
J. H. Donohue, A. K. Stewart and H. R. Menck, “The National Cancer Data Base Report on Carcinoma of the Gallbladder, 1989-1995,” Cancer, Vol. 83, No. 12, 1998, pp. 2618-2628.
doi:10.1002/(SICI)1097-0142(19981215)83:12<2618::AID-CNCR29>3.0.CO;2-H
|
[21]
|
Y. Fong, W. Jarnagin and L. H. Blumgart, “Gallbladder Cancer: Comparison of Patients Presenting Initially for Definitive Operation with Those Presenting after Prior Noncurative Intervention,” Annals of Surgery, Vol. 232, No. 4, 2000, pp. 557-569.
doi:10.1097/00000658-200010000-00011
|
[22]
|
M. Pandey, B. P. Sood, R. C. Shukla, et al., “Carcinoma of the Gallbladder: Role of Sonography in Diagnosis and Staging,” Journal of Clinical Ultrasound, Vol. 28, No. 5, 2000, pp. 227-232.
doi:10.1002/(SICI)1097-0096(200006)28:5<227::AID-JCU4>3.0.CO;2-4
|
[23]
|
J. C. Box and S. B. Edge, “Laparoscopic Cholecystectomy and Unsuspected Gallbladder Carcinoma,” Seminars in Surgical Oncology, Vol. 16, 1999, pp. 327-331.
doi:10.1002/(SICI)1098-2388(199906)16:4<327::AID-SSU8>3.0.CO;2-V
|
[24]
|
W. G. Hawkins, R. P. DeMatteo, W. R. Jarnagin WR, et al., “Jaundice Predicts Advanced Disease and Early Mortality in Patients with Gallbladder Cancer,” Annals of Surgical Oncology, Vol. 11, 2004, pp. 310-315.
doi:10.1245/ASO.2004.03.011
|
[25]
|
M. Artico, E. Bronzetti, V. Alicino, et al., “Human Gallbladder Carcinoma: Role of Neurotrophins, MIB-1, CD34 and CA15-3,” European Journal of Histochemistry, Vol. 54, 2010, p. e10. doi:10.4081/ejh.2010.e10
|
[26]
|
K. Fujii, H. Yokozaki, W. Yasui W, et al., “High Frequency of p53 Gene Mutation in Adenocarcinomas of the Gallbladder,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 5, 1996, pp. 461-466.
|
[27]
|
I. Hatzaras, C. Schmidt, P. Muscarella, et al., “Elevated CA 19-9 Portends Poor Prognosis in Patients Undergoing Resection of Biliary Malignancies,” HPB (Oxford), Vol. 12, No. 2, 2010, pp. 134-138.
doi:10.1111/j.1477-2574.2009.00149.x
|
[28]
|
W. Kwon, J. Y. Jang, S. E. Lee, et al., “Clinicopathologic Features of Polypoid Lesions of the Gallbladder and Risk Factors of Gallbladder Cancer,” Journal of Korean Medical Science, Vol. 24, No. 3, 2009, pp. 481-487.
doi:10.3346/jkms.2009.24.3.481
|
[29]
|
A. H. Patel, D. M. Harnois, G. G. Klee, et al., “The Utility of CA 19-9 in the Diagnoses of Cholangiocarcinoma in Patients without Primary Sclerosing Cholangitis,” American Journal of Gastroenterology, Vol. 95, No. 1, 2000, pp. 204-207.
doi:10.1111/j.1572-0241.2000.01685.x
|
[30]
|
D. C. Buckles, K. D. Lindor, N. F. Larusso, et al., “In Primary Sclerosing Cholangitis, Gallbladder Polyps Are Frequently Malignant,” American Journal of Gastroenterology, Vol. 97, 2002, pp. 1138-1142.
doi:10.1111/j.1572-0241.2002.05677.x
|
[31]
|
T. Itoi, H. Watanabe, M. Yoshida, et al., “Correlation of p53 Protein Expression with Gene Mutation in GallBladder Carcinomas,” Pathology International, Vol. 47, 1997, pp. 525-530.
doi:10.1111/j.1440-1827.1997.tb04535.x
|
[32]
|
A. Wee, M. Teh and G. C. Raju, “Clinical Importance of p53 Protein in Gall Bladder Carcinoma and Its Precursor Lesions,” Journal of Clinical Pathology, Vol. 47, 1994, pp. 453-456. doi:10.1136/jcp.47.5.453
|
[33]
|
S. Tazuma and G. Kajiyama, “Carcinogenesis of Malignant Lesions of the Gall Bladder. The Impact of Chronic Inflammation and Gallstones,” Langenbeck’s Archives of Surgery, Vol. 386, No. 3, 2001, pp. 224-229.
doi:10.1007/s004230100220
|
[34]
|
M. Tada, O. Yokosuka, M. Omata, et al., “Analysis of Ras Gene Mutations in Biliary and Pancreatic Tumors by Polymerase Chain Reaction and Direct Sequencing,” Cancer, Vol. 66, 1990, pp. 930-935.
doi:10.1002/1097-0142(19900901)66:5<930::AID-CNCR2820660519>3.0.CO;2-W
|
[35]
|
K. Hanada, M. Itoh, K. Fujii, et al., “K-ras and p53 Mutations in Stage I Gallbladder Carcinoma with an Anomalous Junction of the Pancreaticobiliary Duct,” Cancer, Vol. 77, 1996, pp. 452-458.
doi:10.1002/(SICI)1097-0142(19960201)77:3<452::AID-CNCR5>3.0.CO;2-M
|
[36]
|
K. Wu, M. Liao, B. Liu and Z. Deng, “ADAM-17 OverExpression in Gallbladder Carcinoma Correlates with Poor Prognosis of Patients,” Medical Oncology, Vol. 28, No. 2, 2011, pp. 475-480.
doi:10.1007/s12032-010-9481-8
|
[37]
|
T. Y. Lee, S. F. Ko, C. C. Huang, et al., “Intraluminal versus Infiltrating Gallbladder Carcinoma: Clinical Presentation, Ultrasound and Computed Tomography,” World Journal of Gastroenterology, Vol. 15, No. 45, 2009, pp. 5662-5668. doi:10.3748/wjg.15.5662
|
[38]
|
T. Wakai, Y. Shirai, N. Yokoyama, et al., “Early Gallbladder Carcinoma Does Not Warrant Radical Resection,” British Journal of Surgery, Vol. 88, No. 5, 2001, pp. 675678. doi:10.1046/j.1365-2168.2001.01749.x
|
[39]
|
Y. Fong, L. Wagman, M. Gonen, et al., “Evidence-Based Gallbladder Cancer Staging: Changing Cancer Staging by Analysis of Data from the National Cancer Database,” Annals of Surgery, Vol. 243, No. 6, 2006, pp. 767-771.
doi:10.1097/01.sla.0000219737.81943.4e
|
[40]
|
I. Endo, H. Shimada, M. Tanabe, et al., “Prognostic Significance of the Number of Positive Lymph Nodes in Gallbladder Cancer,” Journal of Gastrointestinal Surgery, Vol. 10, No. 7, 2006, pp. 999-1007.
doi:10.1016/j.gassur.2006.03.006
|
[41]
|
H. Onoyama, M. Yamamoto, A. Tseng, et al., “Extended Cholecystectomy for Carcinoma of the Gallbladder,” World Journal of Surgery, Vol. 19, No. 5, 1995, pp. 758-763. doi:10.1007/BF00295925
|
[42]
|
Y. Ogura, R. Mizumoto, S. Isaji, et al., “Radical Operations for Carcinoma of the Gallbladder: Present Status in Japan,” World Journal of Surgery, Vol. 15, 1991, pp. 337-343. doi:10.1007/BF01658725
|
[43]
|
H. A. Pitt, “Gallbladder Cancer: What Is an Aggressive Approach?” Annals of Surgery, Vol. 241, No. 3, 2005, pp. 395-396. doi:10.1097/01.sla.0000154119.55201.e9
|
[44]
|
Y. Shirai, T. Wakai and K. Hatakeyama, “Radical Lymph Node Dissection for Gallbladder Cancer: Indications and Limitations,” Surgical Oncology Clinics of North Ameri ca, Vol. 16, 2007, pp. 221-232.
doi:10.1016/j.soc.2006.10.011
|
[45]
|
K. Yamaguchi, K. Chijiiwa, S. Saiki, et al., “Retrospective Analysis of 70 Operations for Gallbladder Carcinoma,” British Journal of Surgery, Vol. 84, No. 2, 1997, pp. 200-204. doi:10.1002/bjs.1800840217
|
[46]
|
T. Todoroki, T. Kawamoto, H. Takahashi, et al., “Treatment of Gallbladder Cancer by Radical Resection,” British Journal of Surgery, Vol. 86, No. 5, 1999, pp. 622-627.
doi:10.1046/j.1365-2168.1999.01085.x
|
[47]
|
E. Dixon, C. M. Vollmer Jr., A. Sahajpal, et al., “An Aggressive Surgical Approach Leads to Improved Survival in Patients with Gallbladder Cancer: A 12-Year Study at a North American Center,” Annals of Surgery, Vol. 241, No. 3, 2005, pp. 385-394.
doi:10.1097/01.sla.0000154118.07704.ef
|
[48]
|
Y. Shirai, T. Ohtani, K. Tsukada and K. Hatakeyama, “Combined Pancreaticoduodenectomy and Hepatectomy for Patients with Locally Advanced Gallbladder Carcinoma: Long Term Results,” Cancer, Vol. 80, 1997, pp. 1904-1909.
doi:10.1002/(SICI)1097-0142(19971115)80:10<1904::AID-CNCR5>3.3.CO;2-Z
|
[49]
|
X. de Aretxabala, I. Roa, M. Berrios, et al., “Chemoradiotherapy in Gallbladder Cancer,” Journal of Surgical Oncology, Vol. 93, No. 8, 2006, pp. 699-704.
doi:10.1002/jso.20538
|
[50]
|
T. Andre, J. M. Reyes-Vidal, L. Fartoux, et al., “Gemcitabine and Oxaliplatin in Advanced Biliary Tract Carcinoma: A Phase II Study,” British Journal of Cancer, Vol. 99, 2008, pp. 862-867. doi:10.1038/sj.bjc.6604628
|
[51]
|
S. R. Alberts, H. Al-Khatib, M. R. Mahoney, et al., “Gemcitabine, 5-Fluorouracil, and Leucovorin in Advanced Biliary Tract and Gallbladder Carcinoma: A North Central Cancer Treatment Group Phase II Trial,” Cancer, Vol. 103, No. 1, 2005, pp. 111-118.
doi:10.1002/cncr.20753
|
[52]
|
T. Takada, H. Amano, H. Yasuda, et al., “Is Postoperative adjuvant Chemotherapy Useful for Gallbladder Carcinoma? A Phase III Multicenter Prospective Randomized Controlled Trial in Patients with Resected Pancreaticobiliary Carcinoma,” Cancer, Vol. 95, No. 8, 2002, pp. 1685-1695. doi:10.1002/cncr.10831
|
[53]
|
V. Gebbia, E. Majello, A. Testa, et al., “Treatment of Advanced Adenocarcinomas of the Exocrine Pancreas and the Gallbladder with 5-Fluorouracil, High Dose Levofolinic Acid and Oral Hydroxyurea on a Weekly Schedule. Results of a Multicenter Study of the Southern Italy Oncology Group (G.O.I.M.),” Cancer, Vol. 78, 1996, pp. 1300-1307.
doi:10.1002/(SICI)1097-0142(19960915)78:6<1300::AID-CNCR19>3.3.CO;2-Y
|
[54]
|
J. S. Park, D. S. Yoon, K. S. Kim, et al., “Actual Recurrence Patterns and Risk Factors Influencing Recurrence after Curative Resection with Stage II Gallbladder Carcinoma,” Journal of Gastrointestinal Surgery, Vol. 11, No. 5, 2007, pp. 631-637. doi:10.1007/s11605-007-0109-z
|